Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Ontology highlight
ABSTRACT: A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks.
SUBMITTER: Cingolani A
PROVIDER: S-EPMC7340855 | BioStudies | 2020-01-01
REPOSITORIES: biostudies
ACCESS DATA